STOCK TITAN

Viatris Inc. - VTRS STOCK NEWS

Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company that bridges the gap between generics and branded medicines, aiming to address healthcare needs more comprehensively worldwide. Formed in November 2020 by the merger of Upjohn, a subsidiary of Pfizer, and Mylan, Viatris leverages its vast portfolio to provide high-quality medications to approximately 1 billion patients annually across more than 165 countries. The company’s operations span 10 major therapeutic areas, with a strategic focus on dermatology, ophthalmology, and gastroenterology.

Viatris boasts an extensive product lineup, including around 1,400 generic pharmaceuticals and several branded medications like Lipitor, Norvasc, Lyrica, and Viagra. Generics and biosimilars form about 40% of its sales, while legacy products contribute to the remaining 60%. The company is also a key supplier of antiretroviral therapies, which nearly 50% of HIV/AIDS patients in developing countries rely on.

In 2023, Viatris continued to make strides with significant developments. It announced positive results from the YUPELRI® Phase III clinical trial in China for COPD treatment, paving the way for regulatory approval anticipated in mid-2024. The company also entered a substantial R&D collaboration with Idorsia Ltd, acquiring global rights to two promising Phase 3 assets: selatogrel, for acute myocardial infarction, and cenerimod, for systemic lupus erythematosus. Additionally, Viatris launched RYZUMVI™, an FDA-approved eye drop for reversing pharmacologically-induced dilation, further expanding its ophthalmology portfolio.

Financially, Viatris demonstrated robust performance with consistent operational revenue growth. The company reported a strong 2023, meeting its financial guidance, and executed strategic initiatives like the divestiture of its Women's Healthcare Business and API business in India. Viatris also maintained a solid cash flow, allowing it to return capital to shareholders through dividends and share repurchases, reinforcing its commitment to shareholder value.

Headquartered in the U.S., with major centers in Pittsburgh, Shanghai, and Hyderabad, Viatris employs around 30,000 people dedicated to advancing global health. For more information, visit viatris.com.

Rhea-AI Summary

Viatris Inc. (NASDAQ: VTRS) has appointed Scott A. Smith as its new CEO, effective April 1, 2023, as the company prepares to advance its Phase 2 strategic plan in 2024. Smith, a seasoned healthcare executive with over 35 years of experience, has been on Viatris' Board since December 2022 and previously held leadership roles at Celgene Corporation and BioAtla, Inc. The board believes Smith's extensive expertise in building and managing complex organizations will be beneficial for Viatris' growth. Former CEO Michael Goettler will assist during the transition before his departure, after having led the company through its initial phase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
management
-
Rhea-AI Summary

Viatris Inc. (NASDAQ: VTRS) has reported meeting its 2022 adjusted guidance, with total revenues reaching $16.263 billion, despite the negative impact of the Biosimilars Transaction and acquired IPR&D. The company confirmed a 2023 revenue growth outlook compared to 2022, excluding the full-year effects of the biosimilars. It increased shareholder returns through $250 million in share repurchases and declared a quarterly dividend of $0.12 per share. Moreover, Viatris paid down approximately $3.3 billion in debt in 2022, contributing to a total reduction of $5.4 billion since 2021, while remaining on track with planned divestitures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
-
Rhea-AI Summary

Viatris Inc. (NASDAQ: VTRS) will announce its fourth quarter and full year 2022 financial results on February 27, before U.S. markets open. The announcement will be followed by a webcast at 8:30 a.m. ET on the same day, featuring insights from CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula. The public can access the live call through investor.viatris.com or by phone. Founded in November 2020, Viatris combines expertise in medicine distribution and sustainability, providing over 1,400 approved molecules in more than 165 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences earnings
Rhea-AI Summary

Viatris shares the inspiring journey of Matt Klein, its senior director of global corporate communications, who began running marathons after being inspired by his sister in 2004. Since then, he has completed over 70 marathons and aims to run in all 50 U.S. states.

After the loss of his father in 2018, he took on a 200-mile run to honor him and has participated in three 200-mile races within four months. Klein has raised over $100,000 for charity through his running endeavors, highlighting the importance of community and resilience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none
-
Rhea-AI Summary

Viatris Inc. (NASDAQ:VTRS) announced a $1 million donation to enhance global access to healthcare, food security, and water stewardship. The funds are allocated to four organizations: Direct Relief, World Central Kitchen, WaterAid, and World Food Program USA. Each organization will receive $250,000 to address pressing global challenges, including the impacts of COVID-19, climate change, and food insecurity. This initiative aligns with Viatris' commitment to the UN Global Compact and Sustainable Development Goals, emphasizing the role of businesses in fostering solutions to societal issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
none
Rhea-AI Summary

Viatris (NASDAQ: VTRS) has completed its acquisitions of Oyster Point Pharma and Famy Life Sciences, forming a new Eye Care Division. The total acquisition prices were approximately $415 million for Oyster Point Pharma and $280 million for Famy Life Sciences, with both transactions anticipated to generate at least $1 billion in sales by 2028. The new division aims to leverage combined expertise to enhance patient access and solidify Viatris' position in the global eye care market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
-
Rhea-AI Summary

Viatris Inc. (NASDAQ: VTRS) has appointed Scott A. Smith and Elisha W. Finney to its board of directors, succeeding retiring members Neil Dimick and Ian Read. Scott Smith, formerly President at Celgene, brings extensive experience in the biotechnology sector, while Finney has a strong financial background from her tenure at Varian Medical Systems. Both new directors are expected to enhance Viatris' strategy for growth and innovation in the pharmaceutical sector. The changes come as the company prepares to advance to its second phase post-Combination in November 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Viatris Inc. (NASDAQ: VTRS) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, in San Francisco. CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will represent the company. A presentation followed by a fireside chat is scheduled for 3 p.m. PST / 6 p.m. EST. Interested parties can access a live webcast at investor.viatris.com, with an archived version available later. Viatris empowers global health through access to medicines and innovative solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
Rhea-AI Summary

On December 14, 2022, Viatris (NASDAQ: VTRS) announced a $1 million donation to enhance healthcare access, food security, and water stewardship worldwide. The contributions, allocated evenly to Direct Relief, World Central Kitchen, WaterAid, and World Food Program USA, align with the company's commitment to the UN Sustainable Development Goals. CEO Michael Goettler emphasized the importance of addressing global challenges such as the COVID-19 pandemic, climate change, and access disparities. This initiative reflects Viatris' mission to empower global health and well-being.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none

FAQ

What is the current stock price of Viatris (VTRS)?

The current stock price of Viatris (VTRS) is $12.52 as of December 20, 2024.

What is the market cap of Viatris (VTRS)?

The market cap of Viatris (VTRS) is approximately 14.7B.

What is Viatris Inc.?

Viatris Inc. is a global healthcare company formed by the merger of Upjohn and Mylan, providing a wide range of generic and branded medications.

What products does Viatris offer?

Viatris offers around 1,400 generic pharmaceuticals and several branded medications like Lipitor, Norvasc, Lyrica, and Viagra.

What are Viatris' key therapeutic areas?

Viatris focuses on 10 major therapeutic areas, with special emphasis on dermatology, ophthalmology, and gastroenterology.

What recent collaborations has Viatris announced?

Viatris announced a significant R&D collaboration with Idorsia Ltd, acquiring global rights to two Phase 3 assets: selatogrel and cenerimod.

How did Viatris perform financially in 2023?

Viatris demonstrated strong financial performance in 2023, meeting its guidance and achieving consistent operational revenue growth.

Where is Viatris headquartered?

Viatris is headquartered in the United States, with major global centers in Pittsburgh, Shanghai, and Hyderabad, India.

What is YUPELRI®?

YUPELRI® is a once-daily nebulized long-acting muscarinic antagonist (LAMA) for COPD maintenance treatment, showing positive results in a Phase III trial in China.

What is the significance of RYZUMVI™?

RYZUMVI™ is an FDA-approved eye drop launched by Viatris for reversing pharmacologically-induced dilation, expanding its ophthalmology portfolio.

What is the mission of Viatris?

Viatris aims to empower people worldwide to live healthier lives by providing access to high-quality medicines at scale, addressing healthcare needs globally.

How many people does Viatris employ?

Viatris employs approximately 30,000 people dedicated to advancing global health.

Viatris Inc.

Nasdaq:VTRS

VTRS Rankings

VTRS Stock Data

14.66B
1.19B
0.41%
82.85%
1.74%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
CANONSBURG